Quanticate

Quanticate

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $75M

Overview

Quanticate is a specialized, service-based biometrics CRO that provides critical statistical, programming, and data management expertise to accelerate clinical trials for pharma and biotech clients. It differentiates itself through deep biometrics specialization, a focus on functional service provision (FSP) and fixed-cost projects, and the integration of AI and automation tools like its QSummarise platform to enhance efficiency. With experience across over 80 therapeutic indications and a global operational footprint, the company positions itself as a trusted partner for complex and rescue studies, from protocol design through to regulatory submission support.

Oncology

Technology Platform

AI and automation platform for clinical data, featuring QSummarise for automated SDTM dataset creation and CDISC mapping. Integrates AI throughout statistical, programming, and data management processes.

Funding History

3
Total raised:$75M
Series C$40M
Series B$25M
Series A$10M

Opportunities

Growing demand for specialized biometrics outsourcing (FSP model) and AI-driven efficiency in clinical trials.
Increasing trial complexity and regulatory data standards (CDISC) create a need for deep expertise.
Expansion into Real World Data analytics and post-marketing studies offers new service avenues.

Risk Factors

Revenue dependency on biopharma R&D cycles.
Intense competition from large full-service CROs and other niche providers.
Execution risk in maintaining regulatory compliance and quality across all client projects.

Competitive Landscape

Competes against large, full-service CROs (e.g., IQVIA, Parexel) and other specialized biometrics/service providers. Differentiation is based on deep biometrics focus, flexible resourcing models, and proprietary AI/automation tools designed to improve data submission speed and quality.